Lymphoma News

Cancer drugs that received accelerated approval from the FDA gained regular approval significantly faster if their confirmatory trials demonstrated meaningful clinical benefits, according to results of a retrospective study.

Cancer mortality gradually declined over the past 2-plus decades, although the rate slowed between 2019 and 2022, according to results of the Annual Report to the Nation on the Status of Cancer.

A grassroots organization that formed with the goal of recalibrating cancer care around patient needs issued guidance intended to improve the design of randomized phase 3 trials.

A common malaria drug could be repurposed to treat a variety of hematologic cancers and solid tumors, according to early study results.

Jonathan Kimmelman, PhD, has published multiple research papers and gotten into an inordinate number of debates about the clinical value of phase 1 trials.

In 2024, both Kate Middleton, Princess of Wales, and King Charles III told the world they had cancer.

Use of immune checkpoint inhibitors in an inpatient setting appeared associated with poor outcomes, according to research published in JCO Oncology Practice.

Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its impact, according to findings published in JCO Oncology Practice.

More than half of patients recently diagnosed with lymphoma or myeloma had clinically significant symptoms of anxiety or depression, according to study results.